Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54,992,500
-
Total 13F shares
-
6,080,809
-
Share change
-
-265,373
-
Total reported value
-
$19,096,287
-
Price per share
-
$3.14
-
Number of holders
-
22
-
Value change
-
-$834,393
-
Number of buys
-
8
-
Number of sells
-
5
Institutional Holders of Candel Therapeutics, Inc. - Common Stock (CADL) as of Q3 2022
As of 30 Sep 2022,
Candel Therapeutics, Inc. - Common Stock (CADL) was held by
22 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,080,809 shares.
The largest 10 holders included
Northpond Ventures, LLC, FRANKLIN RESOURCES INC, FMR LLC, Sands Capital Ventures, LLC, VANGUARD GROUP INC, Point72 Asset Management, L.P., BRIDGEWAY CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., and STATE STREET CORP.
This page lists
22
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.